Kyowa Kirin, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$32.6M
Doctors Paid
21,005
Transactions
66,631
2024 Total
$12.8M
Payment Breakdown by Category
Research$21.1M (64.8%)
Consulting$3.6M (11.0%)
Food & Beverage$1.5M (4.5%)
Travel$771,760 (2.4%)
Royalty/License$46,600 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $21.1M | 1,800 | 64.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.6M | 1,818 | 14.1% |
| Consulting Fee | $3.6M | 1,049 | 11.0% |
| Food and Beverage | $1.5M | 57,790 | 4.5% |
| Travel and Lodging | $771,760 | 3,078 | 2.4% |
| Space rental or facility fees (teaching hospital only) | $485,660 | 149 | 1.5% |
| Honoraria | $329,120 | 133 | 1.0% |
| Education | $174,565 | 805 | 0.5% |
| Royalty or License | $46,600 | 5 | 0.1% |
| Grant | $37,000 | 4 | 0.1% |
Payments by Type
Research
$21.1M
1,800 transactions
General
$11.5M
64,831 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| An open label study to evaluate the safety and efficacy of combination extracorporeal photopheresis (ECP) and mogamulizumab in erythrodermic CTCL | $4.2M | 0 | 26 |
| A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration | $2.1M | 0 | 472 |
| Phase Ib trial of Brentuximab Vedotin in combination with Mogamulizumab in Cutaneous T cell Lymphoma | $1.9M | 0 | 8 |
| A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema | $1.7M | 0 | 446 |
| Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) | $1.1M | 0 | 181 |
| Pilot Study of Concurrent Phototherapy and Mogamulizumab in Early Stage Mycosis Fungoides | $987,618 | 0 | 5 |
| Transformative Research In Diabetic Nephropathy 2.0: A proof of Principle Study of Dapagliflozin | $979,800 | 0 | 1 |
| Proteomic and transcriptomic profiling of alopecia areata | $950,560 | 0 | 4 |
| Study to explore the therapeutic effects of CCR10 targeting via small molecule antagonists in translational IPF models of fibrosis | $598,430 | 0 | 4 |
| Istradefylline effect on Parkinsons Disease Tremor, Motor symptoms and Non-motor symptoms | $555,595 | 0 | 7 |
| Mechanistic and PK study of Apolipoprotein M -Fc (APOM-Fc) | $505,115 | 0 | 1 |
| Istradefylline for Parkinson disease dementia | $495,763 | 0 | 9 |
| An Open-label, Phase 1 Study of KHK2455 in Combination with Avelumab in Adult Subjects with Locally Advanced or Metastatic Urothelial Carcinoma | $435,430 | 0 | 455 |
| Transformative Research In Diabetic Nephropathy | $410,200 | 0 | 1 |
| Molecular Profiling and Immunopathogenesis | $391,408 | 0 | 1 |
| A Prospective, US-based Study Assesing Mogamulizumab-Associated Rash in Patients Diagnosed with Mycosis Fungoides or Sezary Syndrome and Treated with Standard of Care Mogamulizumab | $371,835 | 0 | 1 |
| A phase 2 single?center, single?arm, open?label Mogamulizumab combined upfront with low?dose total skin electron beam therapy (LD?TSEBT) in patients with mycosis fungoides (MF) and S?zary syndrome (SS) | $323,387 | 0 | 1 |
| Phase II study of mogamulizumab with EPOCH in patients with aggressive T cell lymphoma | $244,642 | 0 | 2 |
| A Phase II Study of Combination Extracorporeal Photopheresis (ECP) and Mogamulizumab in Erythrodermic CTCL | $198,765 | 0 | 1 |
| Phase 2 Study for Prevention of Adult T-cell Leukemia/Lymphoma with Mogamulizumab in High Risk Carriers of HTLV-1 | $185,097 | 0 | 2 |
| Kyowa Kirin 2455-002 | $176,312 | 0 | 79 |
| Retrospective Analysis of Standard-of-Care Imaging in Patients with Cutaneous T-Cell Lymphoma to Develop new lymph node response criteria by using novel radiological quantitative techniques | $165,000 | 0 | 2 |
| Compassionate use for single patient IND with Cutaneous-skeletal hypophosphatemia syndrome | $160,252 | 0 | 1 |
| A Phase 2 Study for Screening and Prevention of Adult T-cell Leukemia/Lymphoma with Mogamulizumab in High-Risk Carriers of HTLV-1 | $156,023 | 0 | 1 |
| Antithrombin?(AT)Activity in Women with Severe Preeclampsia(PE) or Superimposed PE prior to 31 weeks | $155,724 | 0 | 2 |
| Characterization TumorHost Interaction that Influences Anti-Tumor Immune Response in Black Patients Vs. White Patients with Mycosis Fungoides and Sezary Syndrome | $150,000 | 0 | 2 |
| Molecular Profiling and Immunopathogenesis. | $130,469 | 0 | 1 |
| Development of new lymph node response criteria by using novel radiological quantitative techniques. | $128,772 | 0 | 2 |
| Antithrobin III (AT) Activity in Women with Severe Preeclampsia (PE) or Superimposed PE prior to 31 weeks. | $102,407 | 0 | 2 |
| Integration of machine learning and genomics to predict outcomes for newly diagnosed, relapsed and refractory mature T-cell and NK-cell neoplasms: a global study of the PETAL Consortium | $99,550 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Stuart Isaacson, Md, MD | Neurology | Boca Raton, FL | $341,559 | $0 |
| Dr. Cherian Karunapuzha, Md, MD | Neurology | Oklahoma City, OK | $299,171 | $0 |
| Ramsey Falconer, M.d, M.D | Neurology | Alexandria, VA | $267,940 | $0 |
| Khashayar Dashtipour, M.d, M.D | Neurology | Loma Linda, CA | $260,175 | $0 |
| Paul Plourde, Md, MD | Endocrinology, Diabetes & Metabolism | West Chester, PA | $233,366 | $0 |
| Dr. Jill Giordano Farmer, Do, DO | Neurology | Philadelphia, PA | $208,727 | $0 |
| Dr. Oleg Akilov, M.d., Ph.d, M.D., PH.D | Dermatology | Pittsburgh, PA | $197,173 | $0 |
| John Morgan, Md, MD | Neurology | Augusta, GA | $184,128 | $0 |
| Dr. Glenn Michelson, M.d, M.D | Hematology & Oncology | Berkeley, CA | $182,828 | $0 |
| Lori Guyton, M.d, M.D | Neurology | Herrin, IL | $181,092 | $0 |
| Nirav Pavasia, M.d, M.D | Neurology | Dallas, TX | $156,011 | $0 |
| Dr. Laxman Bahroo, D.o,, D.O, | Neurology | Washington, DC | $155,469 | $0 |
| Dr. David Kreitzman, M.d, M.D | Neurology | Commack, NY | $153,278 | $0 |
| Dr. Michael Soileau, Md, MD | Neurology | Georgetown, TX | $147,738 | $0 |
| Robert Hauser, Md, MD | Neurology | Tampa, FL | $141,818 | $0 |
| Raja Mehanna, Md, MD | Neurology | Houston, TX | $135,941 | $0 |
| Dr. Eric Rush, M.d, M.D | Clinical Genetics (M.D.) | Kansas City, MO | $135,154 | $0 |
| Dr. Daniel Kremens, M.d., J.d, M.D., J.D | Neurology | Philadelphia, PA | $133,764 | $0 |
| Dr. Alexander Shtilbans, Md, Ph.d, MD, PH.D | Neurology | New York, NY | $128,452 | $0 |
| Dr. Anthony Portale, M.d, M.D | Nephrology | San Francisco, CA | $125,723 | $0 |
| Pinky Agarwal, Md, MD | Specialist | Kirkland, WA | $114,533 | $0 |
| Dr. Yasar Torres-Yaghi, M.d, M.D | Neurology | Washington, DC | $104,100 | $0 |
| Dr. Robert Fekete, M.d, M.D | Neurology | Hawthorne, NY | $103,148 | $0 |
| Madhavi Thomas, M.d, M.D | Neurology | Flower Mound, TX | $102,041 | $0 |
| Linh-Tu Thai, Md, Mph, MD, MPH | Student in an Organized Health Care Education/Training Program | Bryn Mawr, PA | $99,188 | $0 |
Ad
Top Products
- Poteligeo $8.7M
- NOURIANZ $5.7M
Associated Products (7)
Payment Categories
- Food & Beverage $1.5M
- Consulting $3.6M
- Travel & Lodging $771,760
- Research $21.1M
- Royalties $46,600
About Kyowa Kirin, Inc.
Kyowa Kirin, Inc. has made $32.6M in payments to 21,005 healthcare providers, recorded across 66,631 transactions in the CMS Open Payments database. In 2024, the company paid $12.8M. The top product by payment volume is Poteligeo ($8.7M).
Payments were distributed across 210 medical specialties. The top specialty by payment amount is Neurology ($5.4M to 2,697 doctors).
Payment categories include: Food & Beverage ($1.5M), Consulting ($3.6M), Research ($21.1M), Travel & Lodging ($771,760), Royalties ($46,600).
Kyowa Kirin, Inc. is associated with 7 products in the CMS Open Payments database, including Poteligeo, NOURIANZ, and POTELIGEO.